 Home > Active Ingredient News > Blood System > Blood: Compared with CAR-T therapy, auto-HCT is more suitable as a consolidation treatment for DLCLC patients who have achieved partial remission!

Blood: Compared with CAR-T therapy, auto-HCT is more suitable as a consolidation treatment for DLCLC patients who have achieved partial remission!

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

heliox therapy

blood type test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Central point|For DLBCL patients who achieved partial remission after salvage treatment, the two-year PFS of auto-HCT or CAR-T for consolidation treatment was 52% vs 42%, and the two-year OS was 69% vs 47%, respectively
.

Center point | CAR-T

Diffuse large B-cell lymphoma (DLBCL) is a curable disease, and approximately 60% of patients do not require further treatment after initial treatment with anthracycline-based and rituximab-containing therapy
.

However, the prognosis of patients who are not cured by first-line treatment is often poor, and patients with relapsed or refractory DLBCL often need salvage treatment

Lymphoma

At present, the relative efficacy of autologous hematopoietic stem cell transplantation (auto-HCT) and chimeric antigen receptor T cell (CAR-T) therapy as consolidation therapy for DLBCL patients who have achieved partial remission (PR) after salvage chemotherapy is still unclear.

.

stem cell

Using the registry database of the International Center for Blood and Bone Marrow Transplantation, Mazyar and other researchers screened for auto-HCT (2013-2019) or CAR-T+Axicabtagene Ciloleucel (2018-2019) treatment during PR through CT or PET scans.
Of adult DLBCL patients, and then using univariate and multivariate regression models to compare the clinical outcomes between the two cohorts after adjustment for relevant baseline and clinical factors
.

Screening

Prognosis of patients receiving auto-HCT or CAR-T therapy

In univariate analysis, there was no significant difference in 2-year progression-free survival (52% vs 42%; p=0.
1) and 100-day non-relapse mortality (4% vs 2%; p=0.
3) between the two cohorts; but The use of auto-HCT for consolidation therapy was associated with a lower two-year recurrence/progression rate (40% vs 53%; p=0.
05) and an excellent overall survival rate (OS: 69% vs 47%; p=0.
004)
.

The use of auto-HCT for consolidation therapy was associated with a lower two-year recurrence/progression rate (40% vs 53%; p=0.
05) and an excellent overall survival rate (OS: 69% vs 47%; p=0.
004)
.

The use of auto-HCT for consolidation therapy was associated with a lower two-year recurrence/progression rate (40% vs 53%; p=0.

In multivariate regression analysis, the prognosis of patients receiving auto-HCT or CAR-T therapy

In multivariate regression analysis, auto-HCT treatment was associated with a significantly reduced risk of recurrence/progression (HR=1.
49; p=0.
01) and superior OS (HR=1.
63; p=0.
008)
.

Auto-HCT treatment is associated with a significantly reduced risk of recurrence/progression (HR=1.
49; p=0.
01) and superior OS (HR=1.
63; p=0.
008).
Auto-HCT treatment is associated with a significantly reduced risk of recurrence/progression ( HR=1.
49; p=0.
01) is related to superior OS (HR=1.
63; p=0.
008)

In general, for DLBCL patients who have achieved partial remission after salvage treatment, auto-HCT treatment is associated with a lower recurrence rate and higher OS compared with CAR-T treatment
.

These data support auto-HCT as a consolidation therapy for DLBCL patients who are eligible for transplantation and obtain partial remission after salvage treatment

For DLBCL patients achieved partial remission after salvage therapy, compared with the CAR-T treatment, auto-HCT treatment with a lower recurrence rate and related higher OS for salvage therapy after obtaining section DLBCL patients in remission, and CAR-T Compared with treatment, auto-HCT treatment is associated with lower recurrence rate and higher OS

Original source:

Shadman Mazyar, Pasquini Marcelo C, Ahn Kwang Woo et al.

Autologous Transplant versus Chimeric Antigen Receptor T- cell Therapy for Relapsed DLBCL in Partial Remission in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.